AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1842
+0.0442 (+1.41%)
As of 3:10PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.1400
Open3.1400
Bid3.1900 x 3000
Ask3.2000 x 3100
Day's Range3.1300 - 3.3050
52 Week Range1.5400 - 6.1900
Volume829,229
Avg. Volume1,793,076
Market Cap382.05M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire7 days ago

    Research Report Identifies Conagra Brands, W.R. Grace, International Flavors & Fragrances, Spirit Airlines, Sunstone Hotel Investors, and Agenus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire13 days ago

    Agenus Awarded Grant to Enable QS-21 Innovations

    - Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21 - Grant to develop an alternative, novel plant cell-culture based method for QS-21 production LEXINGTON, Mass. , Jan. ...

  • ACCESSWIRE26 days ago

    Major Biotech Deals Making Sector Red Hot

    HENDERSON NV / ACCESSWIRE / December 21, 2018 / Deals like the partnership between Gilead and Agenus are making the biotech industry red hot. Here are some biotech companies to look into. We are highlighting: ...

  • ACCESSWIRE27 days ago

    4 Biotech Stocks Making Moves on Thursday December 20, 2018

    CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The biotech industry has shown tremendous growth over the course of the last several months, as medical experts and professionals have sought to test ...

  • PR Newswire27 days ago

    Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

    FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (GILD) and Agenus Inc. (AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment.  The agreement also includes approximately $1.7 billion in potential future fees and milestones.  Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018.

  • Business Wire27 days ago

    Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

    Gilead Sciences, Inc. (GILD) and Agenus Inc. (AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Amarin Corporation and Agenus

    NEW YORK, NY / ACCESSWIRE / December 17, 2018 / U.S. markets slumped on Friday as bank shares dragged equities lower amidst concerns about global economic slowdown after China’s industrial and sales growth ...

  • GlobeNewswirelast month

    Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer

    Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.

  • Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell
    PR Newswire2 months ago

    Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

    LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , ...

  • PR Newswire2 months ago

    Agenus to Present at the 2018 Jefferies London Healthcare Conference

    LEXINGTON, Mass. , Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...

  • PR Newswire2 months ago

    Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

    - AutoSynVax™ (ASV™), AGEN2003 clinical trials data - Novel targets in colorectal carcinoma (CRC) for off-the-shelf vaccine with pan indication development potential - AGEN2373, a novel, potential best-in-class ...

  • PR Newswire2 months ago

    Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    - 130 patients treated with Agenus' PD-1 & CTLA-4; clinical benefit 63% treated - Recent FDA meeting confirms path to BLA filing; targeted for 2020 - Next-Gen CTLA-4 IND filed; four INDs filed year ...

  • PR Newswire3 months ago

    Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

    LEXINGTON, Mass. , Oct. 31, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , ...

  • PR Newswire3 months ago

    Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

    - Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses LEXINGTON, Mass. , Oct. 20 , 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology ...

  • PR Newswire3 months ago

    Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

    - AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer - AGEN PD-1 & CTLA-4 (AGEN1884) is the most advanced combination in 2L cervical cancer LEXINGTON, ...

  • PR Newswire4 months ago

    Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY

    LEXINGTON, Mass., Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the 2018 Cantor Fitzgerald Global Healthcare Conference at the Intercontinental NY Barclay Hotel.

  • PR Newswire4 months ago

    Agenus Closes $15 Million Partial Royalty Monetization With XOMA

    LEXINGTON, Mass., Sept. 21, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation (XOMA), where XOMA purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte and Merck. Agenus received $15.0 million at closing and retains the majority (67%) of all future royalties and 90% of all milestones from Incyte and Merck.

  • PR Newswire4 months ago

    Agenus Receives Milestone Payment from Incyte

    LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Based on this milestone and under the terms of the agreement, Agenus received a $5 million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Incyte. "This is the fourth antibody from our partnered programs that has advanced into clinical trials, once again proving our commitment to deliver on our existing partnerships," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.

  • AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA
    PR Newswire4 months ago

    AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA

    - Both TCRs discovered by Novel "T-Rx™" Discovery Platform LEXINGTON, Mass. , Sept. 5 , 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing ...

  • PR Newswire4 months ago

    Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City

    LEXINGTON, Mass. , Sept. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies ...

  • PR Newswire5 months ago

    Agenus Receives Second Milestone Payment from Merck

    LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. Based on this milestone and under the terms of the agreement, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck. "We continue to deliver on all milestones with our existing partners." said Garo H. Armen, Ph.D., Chairman and CEO of Agenus.

  • PR Newswire5 months ago

    Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    - Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. ...

  • ACCESSWIRE5 months ago

    Agenus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Agenus Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. To listen ...